| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 Jan 2026 | 22 Jan 2026 |
| Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve the unaudited consolidated and standalone financial results of the Company for the quarter ended December 31 2025 along with the limited review report of the Auditors thereon. Financial results with Limited review report (As Per BSE Announcement Dated On : 29.01.2026) | ||
| Board Meeting | 30 Oct 2025 | 23 Oct 2025 |
| Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2025 ,inter alia, to consider and approve Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Outcome of Board Meeting - Q2FY26 Results (As Per BSE Announcement Dated on 30.10.2025) | ||
| Board Meeting | 31 Jul 2025 | 24 Jul 2025 |
| Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2025 along with the Limited Review Report of the Auditors thereon. Intimation of Outcome of Board Meeting (As per BSE Announcement Dated on 31/07/2025) | ||
| Board Meeting | 27 May 2025 | 27 May 2025 |
| Re-appointment of Dr. Georgia Nikolakopoulou Papathomas as Independent Director subject to approval of shareholders at the ensuing Annual General Meeting. Outcome of Board Meeting (As Per BSE Announcement dated on 27.05.2025) | ||
| Board Meeting | 28 Apr 2025 | 21 Apr 2025 |
| Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2025 inter alia to consider and approve Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Intimation of Outcome of Board Meeting (As per BSE Announcement Dated on 28/04/2025) | ||
| Board Meeting | 19 Mar 2025 | 19 Mar 2025 |
| Disclosure under Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements)Regulations,2015 | ||
Operating margin narrowed to 17% during the quarter, compared with 18.2% in the year ago period, indicating some pressure on profitability despite higher revenues.
Margins also improved notably, with EBITDA margin expanding to 20.5% from 19.1% in Q1FY25.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
